VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in acute care therapies, announced today the commercial launch of a new indication for the company’s oXiris set, which ...
The U.S. FDA has granted emergency use authorizations (EUAs) to Baxter International Inc. for its HF20 Set and ST Set used in continuous renal replacement therapy (CRRT) during the COVID-19 pandemic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results